Titlebook: Diagnosis and Management of Pulmonary Hypertension; James R. Klinger,Robert P. Frantz Book 2015 Springer Science+Business Media New York 2

Brocas-Area

Cardiopulmonary Exercise Testing in Pulmonary Hypertension,of cardiopulmonary exercise testing (CPET) has allowed an early diagnosis of PAH in “at risk” patients or those with suggestive clinical findings. CPET can quantify the degree of exercise impairment, and rule out a pulmonary mechanical limit to exercise. It can also be used to monitor disease progre

强制性

nitroglycerin

Prostacyclin Therapy for Pulmonary Arterial Hypertension,r a long time, the only treatment specifically approved for this devastating disease. As new therapies have emerged for PAH in recent years, the class of prostacyclins has also evolved and several formulations of different prostacyclin analogs, using various routes of delivery, have been tested and

Nmda-Receptor

graphy

Modulation of cGMP Synthesis and Metabolism, soluble or particulate guanylate cyclase by NO or NP, respectively. The primary downstream target of cGMP is cGMP-dependent kinase (PKG) which acts at a variety of intracellular sites to inhibit vasoconstriction, proliferation and hypertrophic responses and phosphodiesterases that are responsible f

Neuralgia

Combination Therapy for the Treatment of Pulmonary Arterial Hypertension,d most patients will experience progression of their disease despite treatment. Presently available medications target four different cellular signaling pathways that have been implicated in the pathogenesis of PAH. It is unclear to what extent each pathway contributes to the progression of pulmonar

季雨

Investigative Therapies in Pulmonary Arterial Hypertension, to treat the disease, no cure is presently available. New treatments for PAH that are able to reverse the abnormal pulmonary vascular remodeling that is responsible for much of this disease are badly needed. To accomplish this goal, novel therapies that target many of the dysfunctional pathways tha

Clinch

Subdue

VAN

Validation of IP Security and Trustapies. This chapter highlights much of our understanding of the basic pathobiology underlying PAH including genetic underpinnings, vasoactive substances, alterations in cell proliferation and apoptosis, inflammation, thrombosis, and endocrine factors.